{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=latanoprost&page=2",
    "query": {
      "intervention": "latanoprost",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 122,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=latanoprost&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=latanoprost&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T10:48:32.081Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07082816",
      "title": "Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 489,
      "start_date": "2025-09-02",
      "completion_date": "2026-04-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-09-30T10:48:32.081Z",
      "location_count": 30,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Garden Grove, California + 25 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07082816"
    },
    {
      "nct_id": "NCT01253902",
      "title": "Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "bimatoprost ophthalmic solution 0.01%",
          "type": "DRUG"
        },
        {
          "name": "travoprost ophthalmic solution 0.004%",
          "type": "DRUG"
        },
        {
          "name": "latanoprost ophthalmic solution 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2010-12",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2012-11-07",
      "last_synced_at": "2026-09-30T10:48:32.081Z",
      "location_count": 1,
      "location_summary": "Rogers, Arkansas",
      "locations": [
        {
          "city": "Rogers",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01253902"
    },
    {
      "nct_id": "NCT02059278",
      "title": "Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "T-2345",
          "type": "DRUG"
        },
        {
          "name": "Xalatan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nephron Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 335,
      "start_date": "2014-01",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2018-08-22",
      "last_synced_at": "2026-09-30T10:48:32.081Z",
      "location_count": 1,
      "location_summary": "El Paso, Texas",
      "locations": [
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02059278"
    },
    {
      "nct_id": "NCT01426464",
      "title": "Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "0.005% Latanoprost dosed once.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nanduri, Padma, M.D., FACS",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2011-09",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2011-08-31",
      "last_synced_at": "2026-09-30T10:48:32.081Z",
      "location_count": 1,
      "location_summary": "Visalia, California",
      "locations": [
        {
          "city": "Visalia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01426464"
    },
    {
      "nct_id": "NCT07048886",
      "title": "Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Rocklatan (netarsudil 0.02% and latanoprost 0.005%)",
          "type": "DRUG"
        },
        {
          "name": "Systane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Center for Sight Las Vegas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2025-07-15",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-03",
      "last_synced_at": "2026-09-30T10:48:32.081Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07048886"
    },
    {
      "nct_id": "NCT00287521",
      "title": "A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open-angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "AL-37807 Ophthalmic Suspension, 1.0%",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost, 0.005% (Xalatan)",
          "type": "DRUG"
        },
        {
          "name": "AL-37807 Vehicle",
          "type": "OTHER"
        },
        {
          "name": "Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2005-11",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2012-03-05",
      "last_synced_at": "2026-09-30T10:48:32.081Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00287521"
    },
    {
      "nct_id": "NCT01917383",
      "title": "A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open-Angle Glaucoma (POAG)",
        "Ocular Hypertension (OHT)"
      ],
      "interventions": [
        {
          "name": "Trabodenoson",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost",
          "type": "DRUG"
        },
        {
          "name": "Timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inotek Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2013-08",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2017-12-02",
      "last_synced_at": "2026-09-30T10:48:32.081Z",
      "location_count": 1,
      "location_summary": "Bristol, Tennessee",
      "locations": [
        {
          "city": "Bristol",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01917383"
    },
    {
      "nct_id": "NCT05790941",
      "title": "Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hypotrichosis"
      ],
      "interventions": [
        {
          "name": "Latanoprost and Minoxidil",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Aneira Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "22 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2023-03-11",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-09-30T10:48:32.081Z",
      "location_count": 1,
      "location_summary": "Indian Wells, California",
      "locations": [
        {
          "city": "Indian Wells",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05790941"
    },
    {
      "nct_id": "NCT06883123",
      "title": "Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Simbrinza 0.2%-1% Ophthalmic Suspension",
          "type": "DRUG"
        },
        {
          "name": "Rocklatan 0.02%-0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Cosopt PF 2%-0.5% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prairie Eye Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-05-14",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-09-30T10:48:32.081Z",
      "location_count": 1,
      "location_summary": "Springfield, Illinois",
      "locations": [
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06883123"
    },
    {
      "nct_id": "NCT06407973",
      "title": "A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "OMNI Surgical System",
          "type": "DEVICE"
        },
        {
          "name": "Latanoprost plus adjunctive glaucoma medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Sight Sciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2024-08-21",
      "completion_date": "2025-01-20",
      "has_results": false,
      "last_update_posted_date": "2025-01-29",
      "last_synced_at": "2026-09-30T10:48:32.081Z",
      "location_count": 2,
      "location_summary": "Petaluma, California • Maryville, Tennessee",
      "locations": [
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Maryville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06407973"
    }
  ]
}